Sr.Rayala.Hypo (SRHHYPOLTD)
Slow GrowerFairStock Score: 53/100 — MIXED
Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹496.55 |
| Market Cap | ₹852.32 Cr |
| P/E Ratio | 9.32 |
| ROCE | 14.86% |
| ROE | 10.82% |
| Dividend Yield | 0.6% |
| Profit Growth | 11.3% |
| Debt/Equity | 0.01 |
| Sales Growth | 22.5% |
| Promoter Holding | 60.45% |
| 52-Week Range | ₹382.4 — ₹624.3 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹565.76 |
Strengths
- Near-zero leverage (D/E 0.01) and Piotroski F-score of 7/9 indicate strong financial health
- Trades below book value: P/B 0.97 vs book value ₹500.73, offering modest margin of safety
- Low P/E of 7.76 and PEG of 0.76 versus 13.05% profit growth suggest attractive earnings valuation
- High promoter holding of 60.45% aligns management interests with minority shareholders
Concerns
- Sales growth is weak at just 1.95%, showing limited top-line expansion
- Commodity chemical business likely lacks pricing power and faces cyclical price swings
- Dividend yield of 0.64% provides little income cushion for investors
- FairStock Score of 49/100 indicates mixed fundamentals and moderate quality
AI Analysis
When I look at Sr.Rayala.Hypo, I see a business that is not going to excite anyone with growth, but it may satisfy those who value a sound balance sheet and a reasonable price. The company earns a return on equity of 10.82% and a return on capital of 14.86%, both respectable for a commodity chemical producer. It carries almost no debt, with a debt-to-equity of 0.01, and the Piotroski F-score of 7/9 suggests the financial health is decent. The stock trades at 7.76 times earnings and 0.97 times book value, meaning I am paying less than the stated net worth for the equity. With book value at ₹500.73 and the price at ₹484.95, the margin of safety is modest but present. The latest quarter shows sales of ₹141 crore and net profit of ₹24 crore, a healthy net margin of roughly 17%, and profit growth of 13.05% is far better than the pedestrian sales growth of 1.95%. That tells me margins are doing the heavy lifting, not volume. Promoters own 60.45%, so their interests are largely aligned with mine. The PEG ratio of 0.76, if the 13% profit growth is sustainable, suggests the market is not overpaying for the earnings power. But I must be honest: this is a commodity chemical business. There is little pricing power, and the low sales growth reminds me that this is not a franchise with a durable moat. The dividend yield of only 0.64% gives me almost nothing to hold while I wait. The FairStock Score of 49 sums it up: a mixed picture. I would want the margin of safety to be larger, or the business to show more pricing power, before I would call this a wonderful business at a fair price. For now, it looks like a fairly simple, conservatively financed operation that deserves a place on my watchlist, not a quick decision.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer